Table 3.
The risk of mortality and composite outcome of ESKD and mortality according to the use of RAS blockers
| Models | Mortality |
ESKD or mortality |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Univariable | 0.644 | 0.412–1.008 | 0.054 | 0.603 | 0.390–0.932 | 0.023 |
| Model 1 | 0.661 | 0.418–1.044 | 0.076 | 0.632 | 0.404–0.989 | 0.045 |
| Model 2 | 0.608 | 0.381–0.969 | 0.036 | 0.587 | 0.373–0.926 | 0.022 |
| Model 3 | 0.544 | 0.333–0.889 | 0.015 | 0.531 | 0.329–0.857 | 0.010 |
CI, confidence interval; ESKD, end-stage kidney disease; HR, hazard ratio.
Model 1 was adjusted for age, sex, body mass index, medical history (diabetes mellitus, coronary artery bypass graft or percutaneous coronary intervention, cerebrovascular accident, and dyslipidemia), and use of beta blockers.
Model 2: Model 1 + adjusted for initial laboratory tests including estimated glomerular filtration rate, blood urea nitrogen, hemoglobin, potassium, and urine albumin.
Model 3: Model 2 + adjusted for cancer type, stages and adjuvant treatment.